A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCL, UCLH and the Francis Crick Institute.
MASCT by Hengrui Yuanzheng Biotechnology for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Kidney Cancer (Renal Cell Cancer).